AAV 유전자 치료 주사제 시장 : 세계 예측(2026-2032년)

The AAV Gene Therapy Injection Market is projected to grow by USD 20.45 billion at a CAGR of 21.66% by 2032.

AAV Gene Therapy Injection: Executive Summary

AAV gene therapy injections use adeno-associated virus vectors to deliver genetic payloads to target cells. The field is shaped by advances in molecular design, manufacturing, clinical development, regulatory science, and long-term patient monitoring. Progress depends on demonstrating durable benefit while managing immune responses, vector production complexity, treatment access, and safety obligations.

From Experimental Platforms to Integrated Therapeutic Systems

The landscape is shifting from isolated product development toward integrated capabilities spanning vector engineering, capsid selection, potency testing, process control, cold-chain logistics, and specialized clinical administration. Developers are placing greater emphasis on patient stratification, endpoint selection, durability assessment, and standardized comparability methods. Manufacturing remains a central constraint because production quality, batch consistency, scalability, and analytical characterization directly influence clinical confidence and regulatory review.

Artificial Intelligence Strengthens Discovery, Development, and Operations

Artificial intelligence can support AAV research by identifying relationships among capsid structure, tissue tropism, payload design, and immune recognition. In development, machine-learning tools may assist biomarker selection, patient identification, trial-site planning, imaging interpretation, and adverse-event signal detection. In manufacturing, data-driven monitoring can help identify process deviations and improve analytical workflows. These applications require validated datasets, explainable models, privacy controls, and human oversight; AI does not replace experimental confirmation or regulatory accountability.

Regional Dynamics Across AAV Gene Therapy Development

North America combines advanced biotechnology infrastructure, specialized clinical centers, and experienced regulatory and manufacturing networks. Europe benefits from strong academic collaboration and coordinated scientific capabilities, while the European Union continues to emphasize harmonized regulatory and quality expectations. Asia-Pacific is expanding translational research, manufacturing capacity, and clinical expertise, with Japan, China, South Korea, India, and Australia contributing distinct capabilities. Latin America is developing specialist treatment and research capacity, although access, reimbursement, and logistics remain important considerations. The Middle East is investing in advanced healthcare infrastructure and precision medicine, while Africa faces wider constraints in specialist services, diagnostics, financing, and supply-chain continuity. Regional progress will depend on local training, sustainable procurement, and cross-border evidence generation.

How ASEAN, BRICS, EU, G7, GCC, and NATO Shape the Ecosystem

ASEAN countries can benefit from shared regulatory learning, regional referral pathways, and coordinated specialist training. BRICS members bring diverse research, manufacturing, and healthcare systems, creating opportunities for collaboration while requiring careful alignment of quality and clinical standards. The European Union supports cross-border scientific and regulatory coordination. G7 members contribute substantial research, healthcare, and policy capacity, while also confronting affordability and long-term outcome challenges. GCC states are strengthening advanced-care infrastructure and may serve as regional treatment hubs. NATO members, considered collectively, span mature biomedical ecosystems and diverse national systems; cooperation in health security, supply resilience, and scientific preparedness can support continuity without substituting for civilian regulatory processes.

Country Perspectives on Research, Manufacturing, and Access

The United States has deep capabilities in vector science, clinical development, manufacturing, and regulatory practice. Canada contributes academic research, specialized healthcare, and public-sector scientific capacity. The United Kingdom, France, Germany, Italy, and Spain benefit from established biomedical institutions and European collaboration, with particular attention to health-technology assessment and equitable access. China is strengthening domestic research, manufacturing, and clinical infrastructure, while Japan has advanced regenerative-medicine expertise and a structured regulatory environment. South Korea is developing biotechnology and manufacturing capabilities. Australia combines strong clinical research with geographically dispersed care delivery. India is expanding biotechnology, clinical, and manufacturing capacity, while Brazil and Mexico are building regional expertise amid access and infrastructure considerations. Russia maintains scientific and healthcare capabilities, though international collaboration, supply continuity, and regulatory interoperability affect development conditions.

Priorities for Leaders Building Sustainable AAV Programs

Industry leaders should prioritize manufacturability and analytical control from the earliest design stage, including scalable processes, robust potency assays, and clear comparability strategies. Clinical programs should incorporate immune profiling, meaningful durability endpoints, long-term follow-up, and transparent risk communication. Partnerships with specialist treatment centers can strengthen administration, patient selection, and post-treatment monitoring. Leaders should also establish resilient supply networks, engage regulators and payers early, and design evidence packages that address real-world outcomes and affordability. Responsible AI governance should include model validation, auditability, cybersecurity, and explicit human decision ownership.

Methodology for a Data-Grounded Executive Assessment

This executive summary uses the specified AAV gene therapy injection market scope and synthesizes established industry themes across vector science, clinical development, manufacturing, regulation, healthcare delivery, regional capacity, and technology adoption. Geographic coverage follows the requested regions, groups, and countries. Claims are qualitative and limited to broadly documented structural conditions; no market estimates, market shares, forecasts, or company-specific assessments are included. Interpretation should be supplemented with current regulatory documents, peer-reviewed studies, clinical-trial records, manufacturing guidance, and country-level health-system evidence.

Conclusion: Execution Quality Will Determine AAV Progress

AAV gene therapy injections are advancing within a highly interdisciplinary environment where scientific promise must be matched by manufacturing reliability, clinical durability, safety monitoring, and practical access. Regional and country capabilities are uneven, making collaboration, workforce development, resilient supply chains, and evidence-based policy important. The strongest programs will integrate responsible innovation with rigorous quality systems and patient-centered delivery, allowing the field to progress while maintaining confidence among clinicians, regulators, patients, and healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AAV Gene Therapy Injection Market, by Indication

• 7.1. Introduction
• 7.2. Hemophilia
• 7.3. Inherited Retinal Disease
• 7.4. Lysosomal Storage Disorders
  • 7.4.1. Fabry Disease
  • 7.4.2. Gaucher Disease
  • 7.4.3. Pompe Disease
• 7.5. Neurological Disorders
  • 7.5.1. Parkinson's Disease
  • 7.5.2. Spinal Muscular Atrophy

8. AAV Gene Therapy Injection Market, by Vector Type

• 8.1. Introduction
• 8.2. AAV2
• 8.3. AAV5
• 8.4. AAV8
• 8.5. AAV9

9. AAV Gene Therapy Injection Market, by Delivery Method

• 9.1. Introduction
• 9.2. Intramuscular
• 9.3. Intrathecal
• 9.4. Intravenous

10. AAV Gene Therapy Injection Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Research Institutes
• 10.4. Specialty Clinics

11. AAV Gene Therapy Injection Market, by Region

• 11.1. Introduction
• 11.2. Asia-Pacific
• 11.3. North America
• 11.4. Latin America
• 11.5. Europe
• 11.6. Middle East
• 11.7. Africa

12. AAV Gene Therapy Injection Market, by Group

• 12.1. Introduction
• 12.2. ASEAN
• 12.3. GCC
• 12.4. European Union
• 12.5. BRICS
• 12.6. G7
• 12.7. NATO

13. AAV Gene Therapy Injection Market, by Country

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. United Kingdom
• 13.7. Germany
• 13.8. France
• 13.9. Russia
• 13.10. Italy
• 13.11. Spain
• 13.12. China
• 13.13. India
• 13.14. Japan
• 13.15. Australia
• 13.16. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. Market Concentration Analysis, 2025
  • 14.2.1. Concentration Ratio (CR)
  • 14.2.2. Herfindahl Hirschman Index (HHI)
• 14.3. Recent Developments & Impact Analysis, 2025
• 14.4. Product Portfolio Analysis, 2025
• 14.5. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abeona Therapeutics Inc.
• 15.2. Adverum Biotechnologies Inc.
• 15.3. Astellas Pharma Inc.
• 15.4. Biogen Inc.
• 15.5. BioMarin Pharmaceutical Inc.
• 15.6. bluebird bio Inc.
• 15.7. Capsida Biotherapeutics
• 15.8. CRISPR Therapeutics AG
• 15.9. CSL Behring LLC
• 15.10. F. Hoffmann-La Roche Ltd.
• 15.11. Gilead Sciences Inc.
• 15.12. Krystal Biotech Inc.
• 15.13. MeiraGTx Holdings PLC
• 15.14. Novartis AG
• 15.15. Pfizer Inc.
• 15.16. PTC Therapeutics
• 15.17. REGENXBIO Inc.
• 15.18. Rocket Pharmaceuticals Inc.
• 15.19. Sangamo Therapeutics Inc.
• 15.20. Sarepta Therapeutics Inc.
• 15.21. Spark Therapeutics Inc.
• 15.22. Takeda Pharmaceutical Company Limited
• 15.23. uniQure N.V.
• 15.24. Voyager Therapeutics Inc.

16. Key Experts